NTLA - インテリア・セラピュ―ティクス (Intellia Therapeutics Inc.) インテリア・セラピュ―ティクス

 NTLAのチャート


 NTLAの企業情報

symbol NTLA
会社名 Intellia Therapeutics Inc (インテリア・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インテリア・セラピューティクス(Intellia Therapeutics Inc.)はゲノム編集会社である。同社はCRISPR/Cas9という生物学的ツールを利用した治療法の開発に従事する。CRISPR/Cas9ゲノム編集システムは2つの成分を含む。Cas9タンパク質は遺伝子のノックアウト・修復・挿入のための自然細胞修復プロセスを開始する分子ハサミのように働く。ガイドRNA配列はCas9を特定の標的デオキシリボ核酸(DNA)配列に認識し導く。同社のセンチネルインビボプログラムは、肝臓へのCRISPR/Cas9複合体の送達のための脂質ナノ粒子(LNP)の使用に焦点を当てる。同社の事業部であるeXtellia Therapeuticsは、免疫腫瘍学・自己免疫性疾患・炎症性疾患の分野におけるCRISPR / Cas9ゲノム編集の応用に従事する。同社の子会社はIntellia Securities Corpを含む。   インテリア・セラピュ―ティクスは米国のライフサイエンス企業。遺伝子改変技術に取り組み、ゲノム編集ツ―ルである「クリスパ―・キャス9(CRISPR/Cas9)」システムを利用し、トランスチレチン・アミロイド症やB型肝炎、アンチトリプシン欠乏症などの治療を可能にする。本社はマサチュ―セッツ州ケンブリッジ。   
本社所在地 40 Erie Street Suite 130 Cambridge MA 02139 USA
代表者氏名 Perry A. Karsen ペリーA.カーセン
代表者役職名 Independent Chairman of the Board
電話番号 +1 857-285-6200
設立年月日 41760
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 195人
url www.intelliatx.com
nasdaq_url https://www.nasdaq.com/symbol/ntla
adr_tso
EBITDA EBITDA(百万ドル) -82.90700
終値(lastsale) 24.21
時価総額(marketcap) 1045887324.93
時価総額 時価総額(百万ドル) 958.62210
売上高 売上高(百万ドル) 29.13100
企業価値(EV) 企業価値(EV)(百万ドル) 653.08410
当期純利益 当期純利益(百万ドル) -82.89400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Intellia Therapeutics Inc revenues increased 25% to $15.1M. Net loss increased 54% to $43.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research_Development - Balancing value increase of 58% to $40.9M (expense) Stock-based Compensation in R&D increase of 64% to $5M (expense).

 NTLAのテクニカル分析


 NTLAのニュース

   Leerink Partners Stick to Their Buy Rating for Intellia Therapeutics By Investing.com  2021/03/02 14:48:20 Investing.com
Leerink Partners Stick to Their Buy Rating for Intellia Therapeutics
   Robert W. Baird Stick to Their Hold Rating for Intellia Therapeutics By Investing.com  2021/02/28 14:45:51 Investing.com
Robert W. Baird Stick to Their Hold Rating for Intellia Therapeutics
   FXNEWS24 |Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Forex Reviews  2021/02/12 11:33:11 FXNews24
Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO Sells $1,552,255.72 in Stock  2021/02/12 11:27:09 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 22,942 shares of the firm’s stock in a transaction that occurred on Friday, February 5th. The shares were sold at an average price of $67.66, for a total value of $1,552,255.72. Following the sale, the chief executive officer now owns 654,803 shares of the company’s stock, […]
   Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Sells $861,675.00 in Stock  2021/02/12 10:43:12 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Jose E. Rivera sold 11,489 shares of the stock in a transaction that occurred on Tuesday, February 9th. The stock was sold at an average price of $75.00, for a total value of $861,675.00. Following the completion of the transaction, the executive vice president now directly owns 129,409 shares of […]
   FXNEWS24 |Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Forex Reviews  2021/02/12 11:33:11 FXNews24
Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO Sells $1,552,255.72 in Stock  2021/02/12 11:27:09 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 22,942 shares of the firm’s stock in a transaction that occurred on Friday, February 5th. The shares were sold at an average price of $67.66, for a total value of $1,552,255.72. Following the sale, the chief executive officer now owns 654,803 shares of the company’s stock, […]
   Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Sells $861,675.00 in Stock  2021/02/12 10:43:12 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Jose E. Rivera sold 11,489 shares of the stock in a transaction that occurred on Tuesday, February 9th. The stock was sold at an average price of $75.00, for a total value of $861,675.00. Following the completion of the transaction, the executive vice president now directly owns 129,409 shares of […]
   John M. Leonard Sells 109,889 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock  2021/02/05 09:24:43 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 109,889 shares of the firm’s stock in a transaction dated Monday, February 1st. The shares were sold at an average price of $64.00, for a total transaction of $7,032,896.00. Following the completion of the sale, the chief executive officer now owns 575,488 shares of the company’s […]
   Raymond James Stick to Their Buy Rating for Intellia Therapeutics By Investing.com  2021/01/08 16:51:48 Investing.com
Raymond James Stick to Their Buy Rating for Intellia Therapeutics
   Raymond James Stick to Their Buy Rating for Intellia Therapeutics By Investing.com  2021/01/08 16:51:48 Investing.com
Raymond James Stick to Their Buy Rating for Intellia Therapeutics
   Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021  2021/01/07 12:30:00 GlobeNewswire
Continued advancement of global Phase 1 study of NTLA-2001, a potentially curative single-course therapy for transthyretin amyloidosis (ATTR)Anticipates…
   The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica  2020/12/29 13:09:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Allakos Inc (NASDAQ: ALLK ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arvinas Inc (NASDAQ: ARVN ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Curis, Inc. (NASDAQ: CRIS ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) Inari Medical Inc (NASDAQ: NARI ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lumos Pharma Inc (NASDAQ: LUMO ) Medicenna Therapeutics Corp (NASDAQ: MDNA ) Myovant Sciences Ltd (NYSE: MYOV ) - announced a licensing deal with Pfizer Inc.
   CRISPR Technology Market Growing Demand to Impact Revenue Share by 2030 | Crispr Therapeutics; Thermo Fisher Scientific; Intellia Therapeutics; Horizon Discovery; Synthego Corporation  2020/12/08 11:56:42 OpenPR
The global CRISPR technology market reached a value of nearly $685.5 million in 2019, having increased at a compound annual growth rate (CAGR) of 35.0% since 2015. The market is expected to grow from $685.5 million in 2019 to $1,654.2
   The Daily Biotech Pulse: Lilly Secures Additional Orders For COVID-19 Antibody Treatment, Decision Day For BioCryst, Kinnate Biopharma To Make Wall Street Debut  2020/12/03 12:46:12 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 2) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Cerevel Therapeutics Holdings Inc (NASDAQ: CERE ) Fate Therapeutics Inc (NASDAQ: FATE ) Generation Bio Co (NASDAQ: GBIO ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Inhibrx Inc (NASDAQ: INBX ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Inspire Medical Systems Inc (NYSE: INSP ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Larimar Therapeutics Inc (NASDAQ: LRMR ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) (reacted to positive outlook for the cancer drug it sold to Ispen, which opens the possibility of realizing potential milestone payments) Myovant Sciences Ltd (NYSE: MYOV ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Olema Pharmaceuticals Inc (NASDAQ: OLMA ) Oncorus Inc (NASDAQ: ONCR ) OncoSec Medical Inc (NASDAQ: ONCS ) Pfizer Inc. (NYSE: PFE ) ( announced U.K. regulatory nod for emergency use of its coronavirus vaccine candidate) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Pulse Biosciences Inc (NASDAQ: PLSE ) Spero Therapeutics Inc (NASDAQ: SPRO ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Dec. 2) Histogen Inc (NASDAQ: HSTO ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) (shares will trade …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 インテリア・セラピュ―ティクス NTLA Intellia Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)